scholarly journals The Present Status and the Future Prospects of Neutron Capture Therapy : A Viewpoint of Radiation Medical Physics and Engineering

2000 ◽  
Vol 56 (6) ◽  
pp. 780-791
Author(s):  
TOORU KOBAYASHI
Keyword(s):  
Neutron Capture ◽  
Present Status ◽  
Medical Physics ◽  
Neutron Capture Therapy ◽  
Future Prospects ◽  
The Future

ChemInform Abstract: The Present Status of Boron-Neutron Capture Therapy for Tumors.

ChemInform ◽  
2010 ◽  
Vol 22 (23) ◽  
pp. no-no
Author(s):  
H. HATANAKA ◽  
W. H. SWEET ◽  
K. SANO ◽  
F. ELLIS
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Present Status ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

scholarly journals Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects

2005 ◽  
Vol 11 (11) ◽  
pp. 3987-4002 ◽  
Author(s):  
Rolf F. Barth ◽  
Jeffrey A. Coderre ◽  
M. Graça H. Vicente ◽  
Thomas E. Blue
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Current Status ◽  
Neutron Capture Therapy ◽  
Future Prospects ◽  
Boron Neutron Capture

The present status of boron-neutron capture therapy for tumors

1991 ◽  
Vol 63 (3) ◽  
pp. 373-374 ◽  
Author(s):  
H. Hatanaka ◽  
W. H. Sweet ◽  
K. Sano ◽  
F. Ellis
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Present Status ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

scholarly journals In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy

Cells ◽  
2020 ◽  
Vol 9 (10) ◽  
pp. 2149
Author(s):  
Atsushi Fujimura ◽  
Seiji Yasui ◽  
Kazuyo Igawa ◽  
Ai Ueda ◽  
Kaori Watanabe ◽  
...  
Keyword(s):  
Amino Acid ◽  
Cell Surface ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Cell Membrane Permeability ◽  
Neutron Capture Therapy ◽  
Translational Machinery ◽  
Boron Neutron Capture ◽  
The Future ◽  
Intracellular Targets

Boron neutron capture therapy (BNCT) requires pharmaceutical innovations and molecular-based evidence of effectiveness to become a standard cancer therapeutic in the future. Recently, in Japan, 4-borono-L-phenylalanine (BPA) was approved as a boron agent for BNCT against head and neck (H&N) cancers. H&N cancer appears to be a suitable target for BPA-BNCT, because the expression levels of L-type amino acid transporter 1 (LAT1), one of the amino acid transporters responsible for BPA uptake, are elevated in most cases of H&N cancer. However, in other types of cancer including malignant brain tumors, LAT1 is not always highly expressed. To expand the possibility of BNCT for these cases, we previously developed poly-arginine peptide (polyR)-conjugated mercaptoundecahydrododecaborate (BSH). PolyR confers the cell membrane permeability and tumor selectivity of BSH. However, the molecular determinants for the properties are not fully understood. In this present study, we have identified the cluster of differentiation 44 (CD44) protein and translational machinery proteins as a major cell surface target and intracellular targets of BSH-polyR, respectively. CD44, also known as a stem cell-associated maker in various types of cancer, is required for the cellular uptake of polyR-conjugated molecules. We showed that BSH-polyR was predominantly delivered to a CD44High cell population of cancer cells. Once delivered, BSH-polyR interacted with the translational machinery components, including the initiation factors, termination factors, and poly(A)-biding protein (PABP). As a proof of principle, we performed BSH-polyR-based BNCT against glioma stem-like cells and revealed that BSH-polyR successfully induced BNCT-dependent cell death specifically in CD44High cells. Bioinformatics analysis indicated that BSH-polyR would be suitable for certain types of malignant tumors. Our results shed light on the biochemical properties of BSH-polyR, which may further contribute to the therapeutic optimization of BSH-BNCT in the future.

scholarly journals Boron Neutron Capture Therapy for Cancer: Future Prospects in Indonesia

2020 ◽  
Vol 35 (3) ◽  
pp. 199-201
Author(s):  
Bagaswoto Poedjomartono ◽  
Hanif Afkari ◽  
Edy Meiyanto ◽  
Alan Bangun ◽  
Yohanes Sardjono
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Lethal Dose ◽  
Low Energy ◽  
Neutron Capture Therapy ◽  
Thermal Neutrons ◽  
Future Prospects ◽  
Alpha Radiation ◽  
Boron Neutron Capture ◽  
High Linear Energy Transfer

Boron neutron capture therapy (BNCT) is a form of cancer therapy based on the interaction of low-energy thermal neutrons and boron-10 (10-B) to produce alpha radiation from He-4 and Li-7 with a high linear energy transfer. A beam of neutrons irradiates a boron drug injected into the tumor, resulting in the boron-injected cancer cells receiving a lethal dose of radiation with the surrounding, healthy cells being minimally affected. Two boron drugs have been used clinically in BNCT, boron sodium captate (BSH) and borophenylalanine (BPA), while a third, pentagamaboronon-0 (PGB-0), is currently under development in the Faculty of Pharmacy of Universitas Gadjah Mada, Indonesia. In Indonesia, there has been a growing interest in the study and use of BNCT to treat cancer, as this method is expected to be safer and more effective than traditional cancer treatment methods.

Overview of hadron therapy: rationales, present status and future prospects

2001 ◽  
Vol 89 (4-5) ◽  
Author(s):  
D.T.L. Jones
Keyword(s):  
Neutron Capture ◽  
Epithermal Neutron ◽  
Biological Effects ◽  
Heavy Ion ◽  
Particle Therapy ◽  
Neutron Capture Therapy ◽  
Hadron Therapy ◽  
The Future ◽  
Charged Particle Therapy ◽  
Cure Rates

The rationales for hadron therapy are based on the physical selectivity and biological effects of the respective beams. Fastneutron therapy began as long ago as 1938 and subsequently proton, alpha particle, heavy ion, pion and neutron capture therapy have beenused. To date it is estimated that in excess of 50000 peoplehave undergone some form of hadron therapy. In the future it isexpected that fast neutron therapy will be used for selected tumourtypes for which neutrons are known to show improved cure rates. Thefuture trends in charged particle therapy will be driven by increasingcommercialization. The future of neutron capture therapy will dependon current clinical trials with epithermal neutron beams and thedevelopment of new tumour-seeking drugs.

Sign in / Sign up

Export Citation Format

Share Document